230 related articles for article (PubMed ID: 25418060)
1. Pharmacological treatment for uterine leiomyosarcomas.
Gadducci A; Guerrieri ME
Expert Opin Pharmacother; 2015 Feb; 16(3):335-46. PubMed ID: 25418060
[TBL] [Abstract][Full Text] [Related]
2. Systematic chemotherapy for inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a systematic review.
Gupta AA; Yao X; Verma S; Mackay H; Hopkins L;
Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):346-55. PubMed ID: 23295078
[TBL] [Abstract][Full Text] [Related]
3. Management of advanced uterine leiomyosarcoma.
Hyman DM; Grisham RN; Hensley ML
Curr Opin Oncol; 2014 Jul; 26(4):422-7. PubMed ID: 24840518
[TBL] [Abstract][Full Text] [Related]
4. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).
Pautier P; Floquet A; Penel N; Piperno-Neumann S; Isambert N; Rey A; Bompas E; Cioffi A; Delcambre C; Cupissol D; Collin F; Blay JY; Jimenez M; Duffaud F
Oncologist; 2012; 17(9):1213-20. PubMed ID: 22907974
[TBL] [Abstract][Full Text] [Related]
5. Mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy for uterine leiomyosarcoma: a report of two cases.
Minobe S; Todo Y; Suzuki Y; Aoyagi Y; Umazume T; Okamoto K; Kato H
J Obstet Gynaecol Res; 2011 Jun; 37(6):645-9. PubMed ID: 21375676
[TBL] [Abstract][Full Text] [Related]
6. Current state of the art and emerging pharmacotherapy for uterine leiomyosarcomas.
Tantari M; Barra F; Di Domenico S; Ferraioli D; Vellone VG; De Cian F; Ferrero S
Expert Opin Pharmacother; 2019 Apr; 20(6):713-723. PubMed ID: 30724615
[TBL] [Abstract][Full Text] [Related]
7. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors.
O'Cearbhaill R; Zhou Q; Iasonos A; Soslow RA; Leitao MM; Aghajanian C; Hensley ML
Gynecol Oncol; 2010 Mar; 116(3):424-9. PubMed ID: 19932916
[TBL] [Abstract][Full Text] [Related]
8. Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation.
Ricci S; Stone RL; Fader AN
Gynecol Oncol; 2017 Apr; 145(1):208-216. PubMed ID: 28209496
[TBL] [Abstract][Full Text] [Related]
9. Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma.
Tewari D; Saffari B; Cowan C; Wallick AC; Koontz MZ; Monk BJ
Gynecol Oncol; 2006 Sep; 102(3):421-4. PubMed ID: 16797679
[TBL] [Abstract][Full Text] [Related]
10. A Case of Uterine Leiomyosarcoma with Long-Term Disease Control by Pazopanib.
Nagamata S; Ebina Y; Yamano Y; Miyamoto T; Nishijima M; Yamada H
Kobe J Med Sci; 2016 Jul; 62(2):E45-8. PubMed ID: 27578036
[TBL] [Abstract][Full Text] [Related]
11. Optimal management of uterine leiomyosarcoma.
O'Cearbhaill R; Hensley ML
Expert Rev Anticancer Ther; 2010 Feb; 10(2):153-69. PubMed ID: 20131992
[TBL] [Abstract][Full Text] [Related]
12. A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma.
Gadducci A; Grosso F; Scambia G; Raspagliesi F; Colombo N; Grignani G; Casali P; Sanfilippo R; Buonadonna A; Santoro A; Bruzzone M; Artioli G; Lorusso D; Biagioli E; Fossati R; Galli F; Negri E; Rulli E; Torri V; D'Incalci M
Br J Cancer; 2018 Aug; 119(5):565-571. PubMed ID: 30057406
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.
Pautier P; Floquet A; Chevreau C; Penel N; Guillemet C; Delcambre C; Cupissol D; Selle F; Isambert N; Piperno-Neumann S; Thyss A; Bertucci F; Bompas E; Alexandre J; Collard O; Lavau-Denes S; Soulié P; Toulmonde M; Le Cesne A; Lacas B; Duffaud F;
Lancet Oncol; 2015 Apr; 16(4):457-64. PubMed ID: 25795402
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy regimen for recurrent uterine leiomyosarcoma.
Hu F; Ye Y; Begum H
J Oncol Pharm Pract; 2024 Mar; 30(2):400-403. PubMed ID: 37787402
[TBL] [Abstract][Full Text] [Related]
15. Stable disease in a patient with metastatic leiomyosarcoma treated with trabectedin.
Tavella K; Villanucci A; Vannini L; Lavacchi D; Montelatici S; Amunni G; Mazzei T
Anticancer Drugs; 2017 Apr; 28(4):465-468. PubMed ID: 28181940
[TBL] [Abstract][Full Text] [Related]
16. Role of chemotherapy and biomolecular therapy in the treatment of uterine sarcomas.
Hensley ML
Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):773-82. PubMed ID: 21752717
[TBL] [Abstract][Full Text] [Related]
17. An increasing role for trabectedin in gynecological cancers: efficacy in uterine sarcomas.
Ray-Coquard I
Int J Gynecol Cancer; 2011 May; 21 Suppl 1():S3-5. PubMed ID: 21540667
[TBL] [Abstract][Full Text] [Related]
18. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers.
Sanfilippo R; Grosso F; Jones RL; Banerjee S; Pilotti S; D'Incalci M; Dei Tos AP; Raspagliesi F; Judson I; Casali PG
Gynecol Oncol; 2011 Dec; 123(3):553-6. PubMed ID: 21917307
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic drug evaluation of pazopanib for the treatment of uterine leiomyosarcomas.
Ferrero S; Leone Roberti Maggiore U; Aiello N; Barra F; Ditto A; Bogani G; Raspagliesi F; Lorusso D
Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):881-889. PubMed ID: 28678537
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma: Trends and survival outcomes.
Littell RD; Tucker LY; Raine-Bennett T; Palen TE; Zaritsky E; Neugebauer R; Embry-Schubert J; Lentz SE
Gynecol Oncol; 2017 Oct; 147(1):11-17. PubMed ID: 28747255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
